Generare is a biotechnology and artificial intelligence company headquartered in Paris, France, focused on commercial bioprospecting and decoding natural products.
Subscribe to see Generare’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Generare is a drug discovery company headquartered in Paris, France. It has raised at least $28M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $23M in April 2026. Xcout tracks 1 named person at Generare, including Guillaume Vandenesch (co-founder and Chief Executive).
As of 16 November 2026. Source: Xcout Intel.
At least $28M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $23M | 5 named | |
| Seed | $5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Generare's closest competitors — see the full list of competitors and alternatives →
Iktos is a privately held biotechnology company headquartered in Paris, France, specializing in generative AI and robotics for drug discovery. Its generative AI platform, Makya, designs molecules optimized for robotic synthesis.
Gero is a biotechnology company headquartered in Singapore with a U.S. subsidiary, combining physics, biology, and artificial intelligence to decode human biology and develop life-changing medicines.
Variational AI is a privately held biotechnology startup headquartered in Vancouver, British Columbia. Founded in 2019, the company focuses on drug discovery, utilizing artificial intelligence to identify novel drug-like small molecules. Recognized as an innovative AI enterprise in Canada, it develops advanced computational methods for pharmaceutical research.
Coding Bio is an Oxford-based biotechnology company that combines a high-throughput wet lab and machine learning platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs.
Cassidy Bio is an AI-first biotechnology company founded in 2024 and based in Israel that is developing a programmable platform for gene editing. The company utilizes a genomic foundation model powered by artificial intelligence to design safer and more scalable gene editing therapies across various guides, editors, and delivery contexts.
Mana.bio is an AI-based drug delivery startup headquartered in Tel Aviv, Israel, focusing on gene therapy and lipid nanoparticle development for mRNA and oligonucleotide therapeutics. The company leverages artificial intelligence to create advanced platforms for next-generation vaccines and genetic medicines.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Generare? Suggest a correction · Work at Generare? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.